These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 23471048)

  • 21. Novel therapeutic strategies in infection and cancer management.
    Clayton P
    Curr Aging Sci; 2012 Dec; 5(3):218-24. PubMed ID: 23387881
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibitory and Coactivating Receptors Recognising the Same Ligand: Immune Homeostasis Exploited by Pathogens and Tumours.
    Levi-Schaffer F; Mandelboim O
    Trends Immunol; 2018 Feb; 39(2):112-122. PubMed ID: 29066058
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Small molecule drugs with immunomodulatory effects in cancer.
    Murphy AG; Zheng L
    Hum Vaccin Immunother; 2015; 11(10):2463-8. PubMed ID: 26110550
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Designing multivalent proteins based on natural killer cell receptors and their ligands as immunotherapy for cancer.
    Smits NC; Coupet TA; Godbersen C; Sentman CL
    Expert Opin Biol Ther; 2016 Sep; 16(9):1105-12. PubMed ID: 27248342
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Designing In and Around Tolerability Considerations for Immunotherapy Combinations.
    Stroh M
    Clin Pharmacol Ther; 2018 Apr; 103(4):558-561. PubMed ID: 29226337
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cancer immunotherapy targeting the CD47/SIRPα axis.
    Weiskopf K
    Eur J Cancer; 2017 May; 76():100-109. PubMed ID: 28286286
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Introduction.
    Liu J; Xu J
    Adv Exp Med Biol; 2020; 1248():1-6. PubMed ID: 32185704
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nanoparticle Delivery of Immunostimulatory Agents for Cancer Immunotherapy.
    Zhuang J; Holay M; Park JH; Fang RH; Zhang J; Zhang L
    Theranostics; 2019; 9(25):7826-7848. PubMed ID: 31695803
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Technological Evolution in the Development of Therapeutic Antibodies.
    Fajardo-Ramírez ÓR; Ascacio-Martínez JA; Licea-Navarro AF; Villela-Martínez LM; Barrera-Saldaña HA
    Rev Invest Clin; 2015; 67(3):158-69. PubMed ID: 26202739
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Histone deacetylase inhibitors as immunomodulators in cancer therapeutics.
    Shen L; Orillion A; Pili R
    Epigenomics; 2016 Mar; 8(3):415-28. PubMed ID: 26950532
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The immunological synapse as a pharmacological target.
    Finetti F; Baldari CT
    Pharmacol Res; 2018 Aug; 134():118-133. PubMed ID: 29898412
    [TBL] [Abstract][Full Text] [Related]  

  • 32. JAMA Oncology Patient Page. Immune Checkpoint Inhibitors.
    West HJ
    JAMA Oncol; 2015 Apr; 1(1):115. PubMed ID: 26182315
    [No Abstract]   [Full Text] [Related]  

  • 33. Immunotherapies targeting stimulatory pathways and beyond.
    Marin-Acevedo JA; Kimbrough EO; Manochakian R; Zhao Y; Lou Y
    J Hematol Oncol; 2021 May; 14(1):78. PubMed ID: 33980266
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunotherapy a New Hope for Cancer Treatment: A Review.
    Nouri Rouzbahani F; Shirkhoda M; Memari F; Dana H; Mahmoodi Chalbatani G; Mahmoodzadeh H; Samarghandi N; Gharagozlou E; Mohammadi Hadloo MH; Maleki AR; Sadeghian E; Nia E; Nia N; Hadjilooei F; Rezaeian O; Meghdadi S; Miri S; Jafari F; Rayzan E; Marmari V
    Pak J Biol Sci; 2018; 21(3):135-150. PubMed ID: 30187723
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Harnessing co-stimulatory TNF receptors for cancer immunotherapy: Current approaches and future opportunities.
    Waight JD; Gombos RB; Wilson NS
    Hum Antibodies; 2017; 25(3-4):87-109. PubMed ID: 28085016
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rationale for anti-OX40 cancer immunotherapy.
    Aspeslagh S; Postel-Vinay S; Rusakiewicz S; Soria JC; Zitvogel L; Marabelle A
    Eur J Cancer; 2016 Jan; 52():50-66. PubMed ID: 26645943
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In silico prediction of cancer immunogens: current state of the art.
    Doytchinova IA; Flower DR
    BMC Immunol; 2018 Mar; 19(1):11. PubMed ID: 29544447
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combining immunotherapy and natural immune stimulants: mechanisms and clinical implications.
    Lucius K; Hill J
    J Cancer Res Clin Oncol; 2019 Oct; 145(10):2633-2635. PubMed ID: 30673870
    [No Abstract]   [Full Text] [Related]  

  • 39. Bacteriology: a caring culture.
    DeWeerdt S
    Nature; 2013 Dec; 504(7480):S4-5. PubMed ID: 24352362
    [No Abstract]   [Full Text] [Related]  

  • 40. Design and Encapsulation of Immunomodulators onto Gold Nanoparticles in Cancer Immunotherapy.
    Chauhan A; Khan T; Omri A
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360803
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.